# Business Case: Patient Adherence Platform

## Executive Summary

The Patient Adherence Platform addresses a $100B+ market opportunity in infusion center operations by converting preventable no-shows into captured revenue while improving patient outcomes. Using LLM-powered conversational AI with behavioral science principles, the platform achieves 40%+ reduction in preventable no-shows.

## The Problem: The Empty Chair

### Market Context
- **$100B** infusion center industry in the US
- **30%** of infusion chairs sit empty due to no-shows and cancellations
- **Infliximab** (and similar biologics): high volume, high margin, low adherence

### Clinical Impact
- **<70%** adherence rate for IV biologics (modifiable through digital intervention)
- **2-3×** higher hospitalization risk with nonadherence (Crohn's disease)
- **~90%** higher medical costs for nonadherent patients

### Root Causes of Nonadherence (All Addressable)
1. **Logistical friction**: Travel burden, scheduling inflexibility
2. **Medication concerns**: Safety fears, perceived necessity
3. **Psychosocial factors**: Anxiety, depression, health literacy
4. **Treatment burden**: Adherence declines over time
5. **Socioeconomic barriers**: Insurance, access to support

## The Solution

### Core Capabilities
- **Behavioral nudging**: Evidence-based strategies (social proof, loss aversion, positive reinforcement)
- **Autonomous tool calling**: Scheduling, transportation, education, copay assistance
- **EHR integration**: FHIR-ready design for seamless clinical workflow
- **Multi-modal engagement**: SMS, WhatsApp, patient portal integration

### Differentiation
- Physician-designed clinical workflows
- Regulatory-aware implementation (HIPAA, FDA considerations)
- Health economics-driven design
- Real-world deployment experience informing product

## Financial Model

### Revenue Assumptions (Conservative)

**Marginal Revenue per Infusion**: $1,000  
*Note: This is intentionally conservative for modeling purposes. Published data shows:*
- Hospital-based infusion centers: $3,000-$5,000
- Ambulatory infusion centers: $2,000-$4,000  
- Physician office-based: $1,500-$3,000
- Some high-complexity infusions: $7,000+

The $1,000 figure allows for easy multiplication and represents a floor, not a ceiling.

**Baseline No-Show Rate**: 12% (industry standard for chronic disease infusions)

**Capture Rate**: 40% of preventable no-shows (based on digital health intervention studies)

### Revenue Recovery by Scale

| Patient Panel | Annual Infusions | Preventable No-Shows | Revenue Recovery* |
|--------------|------------------|---------------------|------------------|
| 500 | 3,000 | 360 | $240,000 |
| 1,000 | 6,000 | 720 | $480,000 |
| 2,000 | 12,000 | 1,440 | $960,000 |
| 9,000 | 54,000 | 6,480 | $4.3M |

*40% capture rate, $1,000/infusion

**Key Metric**: $480 revenue recovery per patient per year

### Cost Structure

**Phase 1 (MVP)**: 
- Development: $50K-$100K (one-time)
- Integration: $25K-$50K (EHR/FHIR)
- Pilot operations: $10K/month

**Ongoing**:
- Platform fees: $5-$10/patient/month
- Support & maintenance: 15-20% of recurring revenue

**Payback Period**: 6-12 months for mid-size practices (500-1,000 patients)

## Implementation Roadmap

### Phase 1: MVP Pilot (0-3 months)
- Behavioral nudge framework
- A/B testing infrastructure
- Single-condition focus (infliximab)

**Success Criteria**:
- ≥20% patient opt-in rate
- ≥40% sustained engagement
- ≥60% appointment confirmation rate
- +5-10% arrival rate improvement
- 0 safety events

### Phase 2: Evaluation & Safety (3-5 months)
- Operational integration
- Safety monitoring
- Outcomes measurement

### Phase 3: Modular Expansion (5-12 months)
- Transportation coordination
- Health education library
- Copay assistance integration
- Multi-language support

### Phase 4: Condition Expansion (12+ months)
- Expand to other biologics (adalimumab, ustekinumab, etc.)
- Oncology infusions
- Chronic disease management beyond infusions

## Market Opportunity

### Target Segments

**Primary**: Hospital-based infusion centers
- 3,000+ facilities in US
- Average 500-2,000 chronic patients per facility
- Highest margin operations

**Secondary**: Ambulatory infusion centers
- Growing segment (shift from hospital-based)
- 1,500+ facilities
- Private equity interest

**Tertiary**: Integrated delivery networks
- Population health focus
- Value-based care alignment

### Competitive Landscape

**Existing Solutions**:
- Basic appointment reminders (SMS/email) - no behavioral intelligence
- EHR-native scheduling - limited engagement capability
- Patient portals - low adoption rates

**Our Advantages**:
- Physician-designed clinical workflows
- LLM-powered personalization
- Behavioral science foundation
- Modular, EHR-agnostic architecture

## Risk Mitigation

### Clinical Risks
- **Mitigation**: Physician oversight, safety escalation protocols, clinical validation

### Regulatory Risks  
- **Mitigation**: HIPAA-compliant architecture, FDA Digital Health Center of Excellence guidance alignment

### Adoption Risks
- **Mitigation**: Pilot-driven approach, minimize workflow disruption, demonstrate ROI early

### Technology Risks
- **Mitigation**: Proven LLM infrastructure (Gemini), graceful degradation, human escalation

## Next Steps

1. **Pilot partner identification**: 1-2 infusion centers (500-1,000 patients)
2. **IRB submission**: Prospective evaluation protocol
3. **EHR integration**: FHIR API implementation
4. **90-day pilot**: Demonstrate capture rate and safety
5. **Publication strategy**: Real-world evidence generation

---

**For detailed implementation timeline and ROI calculator, see**: [Full Presentation](Patient_Adherence_Platform_Presentation.pdf)

**Questions?** Contact Anna Kuperberg, MD at kuperberg.anna@gmail.com
